Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

Tumor marker analyses from the phase III, placebo-controlled, FASTACT-2 study of intercalated erlotinib with gemcitabine/platinum in the first-line treatment of advanced non-small-cell lung cancer

© 2016 The Authors. Objectives: The FASTACT-2 study of intercalated erlotinib with chemotherapy in Asian patients found that EGFR mutations were the main driver behind the significant progression-free survival (PFS) benefit noted in the overall population. Further exploratory biomarker analyses were...

Full description

Saved in:
Bibliographic Details
Main Authors: Tony Mok, Guia Ladrera, Vichien Srimuninnimit, Virote Sriuranpong, Chong Jen Yu, Sumitra Thongprasert, Jennifer Sandoval-Tan, Jin Soo Lee, Fatima Fuerte, David S. Shames, Barbara Klughammer, Matt Truman, Pablo Perez-Moreno, Yi Long Wu
Format: Journal
Published: 2018
Subjects:
Biochemistry, Genetics and Molecular Biology
Medicine
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84966701371&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/55172
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University

Internet

https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84966701371&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/55172

Similar Items